cethromycin

Also known as Abbott-195773, A-195773, ABT-773, Restanza

Cethromycin, trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

Chemical data

Formula: C42H59N3O10
Molecular weight: 765.9 g/mol
IUPAC name: (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone

via PubChem

Drug data · ChEMBL

Max clinical phase: Phase 3
Molecule type: Small molecule
Indications: pneumonia

via ChEMBL · EBI

Research

148 papers

Cethromycin: a new ketolide antibiotic.The Annals of pharmacotherapy · 2013
Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773.Drugs in R&D · 2007
Cethromycin: a promising new ketolide antibiotic for respiratory infections.Pharmacotherapy · 2010
The antimicrobial activity of cethromycin against Staphylococcus aureus and compared with erythromycin and telithromycin.BMC microbiology · 2023
Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.Expert opinion on investigational drugs · 2008

via PubMed

Wikidata facts

Mass: 765.420045

Show 3 more facts

chemical formula: C₄₂H₅₉N₃O₁₀
canonical SMILES: CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OCC=Cc4cc5ccccc5nc4)C)C)NC(=O)O2)C
isomeric SMILES: CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC\C=C\c4cc5ccccc5nc4)C)C)NC(=O)O2)C

Sources (2)

via Wikidata · CC0

~1 min read

Article

2 sections

Contents

References
Further reading

On October 1, 2008, Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.